miR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma

Kaufman, 2008, Current concepts in malignant pleural mesothelioma, Expert Rev Anticancer Ther, 8, 293, 10.1586/14737140.8.2.293

Hansen, 1998, Environmental exposure to crocidolite and mesothelioma: exposure-response relationships, Am J Respir Crit Care Med, 157, 69, 10.1164/ajrccm.157.1.96-11086

Robinson, 2005, Advances in malignant mesothelioma, N Engl J Med, 353, 1591, 10.1056/NEJMra050152

Sugarbaker, 1999, Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients, J Thorac Cardiovasc Surg, 117, 54, 10.1016/S0022-5223(99)70469-1

Vogelzang, 2003, Phase III study of PEM in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136

Hurwitz, 2012, Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent, Eur J Cancer, 48, 1096, 10.1016/j.ejca.2011.11.009

Vandermeers, 2009, Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma, Clin Cancer Res, 15, 2818, 10.1158/1078-0432.CCR-08-1579

Ramalingam, 2007, Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies, Clin Cancer Res, 13, 3605, 10.1158/1078-0432.CCR-07-0162

Zitvogel, 2006, Cancer despite immunosurveillance: immunoselection and immunosubversion, Nat Rev Immunol, 6, 715, 10.1038/nri1936

Zou, 2005, Immunosuppressive networks in the tumour environment and their therapeutic relevance, Nat Rev Cancer, 5, 263, 10.1038/nrc1586

Seike, 2007, Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier, J Natl Cancer Inst, 99, 1257, 10.1093/jnci/djm083

Okamura, 1995, Cloning of a new cytokine that induces IFN-gamma production by T cells, Nature, 378, 88, 10.1038/378088a0

Coughlin, 1998, Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis, J Clin Invest, 101, 1441, 10.1172/JCI1555

Son, 2001, Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells, Cancer Res, 61, 884

Park, 2007, The dual effects of interleukin-18 in tumor progression, Cell Mol Immunol, 4, 329

Johnson, 2005, Ras is regulated by the let-7 microRNA family, Cell, 120, 635, 10.1016/j.cell.2005.01.014

Lu, 2005, MicroRNA expression profiles classify human cancers, Nature, 435, 834, 10.1038/nature03702

Yanaihara, 2006, Unique microRNA molecular profiles in lung cancer diagnosis and prognosis, Cancer Cell, 9, 189, 10.1016/j.ccr.2006.01.025

Seike, 2009, MiR-21 is an EGFR-regulated anti-apoptonic factor in lung cancer in never-smokers, Proc Natl Acad Sci USA, 106, 12085, 10.1073/pnas.0905234106

Pass, 2010, hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma, Cancer Res, 70, 1916, 10.1158/0008-5472.CAN-09-3993

Cioce, 2013, Protumorigenic effects of miR-145 loss in malignant pleural mesothelioma, Oncogene

Shimokawa, 2012, Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules, Br J Cancer, 106, 867, 10.1038/bjc.2012.7

Gemma, 2006, Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database, BMC Cancer, 6, 174, 10.1186/1471-2407-6-174

Kitamura, 2014, MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells, Mol Cancer Ther, 13, 444, 10.1158/1535-7163.MCT-13-0448

Thodtmann, 1999, Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin, J Clin Oncol, 17, 3009, 10.1200/JCO.1999.17.10.3009

Fakih, 2009, A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer, Clin Cancer Res, 15, 3189, 10.1158/1078-0432.CCR-08-2999

Miyanaga, 2008, Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model, Mol Cancer Ther, 7, 1923, 10.1158/1535-7163.MCT-07-2140

Dinarello, 2006, The paradox of pro-inflammatory cytokines in cancer, Cancer Metastasis Rev, 25, 307, 10.1007/s10555-006-9000-8

Pollari, 2012, Identification of microRNAs inhibiting TGF-β-induced IL-11 production in bone metastatic breast cancer cells, PLoS One, 7, e37361, 10.1371/journal.pone.0037361

Khan, 2013, miR-379 regulates cyclin B1 expression and is decreased in breast cancer, PLoS One, 8, e68753, 10.1371/journal.pone.0068753

Yao, 2011, Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox, PLoS One, 6, e24684, 10.1371/journal.pone.0024684

Terme, 2011, IL-18 induces PD-1-dependent immunosuppression in cancer, Cancer Res, 71, 5393, 10.1158/0008-5472.CAN-11-0993